Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gokhan Tut

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Open Forum Infectious Diseases|January 30, 2023
Clinical Effectiveness of SARS-CoV-2 Booster Vaccine Against Omicron Infection in Residents and Staff of Long-term Care Facilities: A Prospective Cohort Study (VIVALDI)Oliver Stirrup, Madhumita Shrotri, Natalie L Adams, et al.
The Lancet. Healthy Longevity|August 17, 2021
Immunogenicity of single vaccination with BNT162b2 or ChAdOx1 nCoV-19 at 5-6 weeks post vaccine in participants aged 80 years or older: an exploratory analysisHelen Parry, Rachel Bruton, Gokhan Tut, et al.
The Journal of Infection|September 3, 2023
Nasal mucosal IgA levels against SARS-CoV-2 and seasonal coronaviruses are low in children but boosted by reinfectionAlexander C Dowell, Gokhan Tut, Jusnara Begum, et al.
Communications Biology|January 3, 2026
Endemic penetrance of SARS-CoV-2 has impacted marginally on immunity to spike protein of human coronavirusesTara Lancaster, Gokhan Tut, Panagiota Sylla, et al.
The Lancet. Healthy Longevity|August 25, 2021
Profile of humoral and cellular immune responses to single doses of BNT162b2 or ChAdOx1 nCoV-19 vaccines in residents and staff within residential care homes (VIVALDI): an observational studyGokhan Tut, Tara Lancaster, Maria Krutikov, et al.
The Journal of Infectious Diseases|April 16, 2022
Severe Acute Respiratory Syndrome Coronavirus 2 Anti-Spike Antibody Levels Following Second Dose of ChAdOx1 nCov-19 or BNT162b2 Vaccine in Residents of Long-term Care Facilities in England (VIVALDI)Oliver Stirrup, Maria Krutikov, Gokhan Tut, et al.
The Lancet. Healthy Longevity|July 11, 2022
Antibody and cellular immune responses following dual COVID-19 vaccination within infection-naive residents of long-term care facilities: an observational cohort studyGokhan Tut, Tara Lancaster, Panagiota Sylla, et al.
Elife|September 29, 2021
mRNA vaccination in people over 80 years of age induces strong humoral immune responses against SARS-CoV-2 with cross neutralization of P.1 Brazilian variantHelen Parry, Gokhan Tut, Rachel Bruton, et al.
Nature Aging|April 28, 2023
Strong peak immunogenicity but rapid antibody waning following third vaccine dose in older residents of care homesGokhan Tut, Tara Lancaster, Maria Krutikov, et al.
Nature Aging|April 28, 2023
Robust SARS-CoV-2-specific and heterologous immune responses in vaccine-naïve residents of long-term care facilities who survive natural infectionGokhan Tut, Tara Lancaster, Megan S Butler, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Open Forum Infectious Diseases|January 30, 2023
Clinical Effectiveness of SARS-CoV-2 Booster Vaccine Against Omicron Infection in Residents and Staff of Long-term Care Facilities: A Prospective Cohort Study (VIVALDI)Oliver Stirrup, Madhumita Shrotri, Natalie L Adams, et al.
The Lancet. Healthy Longevity|August 17, 2021
Immunogenicity of single vaccination with BNT162b2 or ChAdOx1 nCoV-19 at 5-6 weeks post vaccine in participants aged 80 years or older: an exploratory analysisHelen Parry, Rachel Bruton, Gokhan Tut, et al.
The Journal of Infection|September 3, 2023
Nasal mucosal IgA levels against SARS-CoV-2 and seasonal coronaviruses are low in children but boosted by reinfectionAlexander C Dowell, Gokhan Tut, Jusnara Begum, et al.
Communications Biology|January 3, 2026
Endemic penetrance of SARS-CoV-2 has impacted marginally on immunity to spike protein of human coronavirusesTara Lancaster, Gokhan Tut, Panagiota Sylla, et al.
The Lancet. Healthy Longevity|August 25, 2021
Profile of humoral and cellular immune responses to single doses of BNT162b2 or ChAdOx1 nCoV-19 vaccines in residents and staff within residential care homes (VIVALDI): an observational studyGokhan Tut, Tara Lancaster, Maria Krutikov, et al.
The Journal of Infectious Diseases|April 16, 2022
Severe Acute Respiratory Syndrome Coronavirus 2 Anti-Spike Antibody Levels Following Second Dose of ChAdOx1 nCov-19 or BNT162b2 Vaccine in Residents of Long-term Care Facilities in England (VIVALDI)Oliver Stirrup, Maria Krutikov, Gokhan Tut, et al.
The Lancet. Healthy Longevity|July 11, 2022
Antibody and cellular immune responses following dual COVID-19 vaccination within infection-naive residents of long-term care facilities: an observational cohort studyGokhan Tut, Tara Lancaster, Panagiota Sylla, et al.
Elife|September 29, 2021
mRNA vaccination in people over 80 years of age induces strong humoral immune responses against SARS-CoV-2 with cross neutralization of P.1 Brazilian variantHelen Parry, Gokhan Tut, Rachel Bruton, et al.
Nature Aging|April 28, 2023
Strong peak immunogenicity but rapid antibody waning following third vaccine dose in older residents of care homesGokhan Tut, Tara Lancaster, Maria Krutikov, et al.
Nature Aging|April 28, 2023
Robust SARS-CoV-2-specific and heterologous immune responses in vaccine-naïve residents of long-term care facilities who survive natural infectionGokhan Tut, Tara Lancaster, Megan S Butler, et al.
Pageof 3